Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Effect of acupuncture therapy on appetite of obesity patients].

Zhen ci yan jiu = Acupuncture research·2013
Same author

On the evolutionary history, population genetics and diversity among isolates of Salmonella Enteritidis PFGE pattern JEGX01.0004.

PloS one·2013
Same author

Colonization and internalization of Salmonella enterica in tomato plants.

Applied and environmental microbiology·2013
Same author

Image-based modeling and precision medicine: patient-specific carotid and coronary plaque assessment and predictions.

IEEE transactions on bio-medical engineering·2013
Same author

Recombination and functional studies of a dual-action peptide for diabetes.

Journal of drug targeting·2013
Same author

Comparative molecular dynamics study of human islet amyloid polypeptide (IAPP) and rat IAPP oligomers.

Biochemistry·2013

Related Experiment Video

Updated: Jun 23, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K

Case Report: Posterior reversible encephalopathy syndrome after lenvatinib treatment for hepatocellular carcinoma.

Minchun Chen1, Jing Shen2, Rongrong Jia3

  • 1Department of Pharmacy, Xi'an No.3 Hospital, The Affiliated Hospital of Northwest University, Xi'an, China.

Frontiers in Pharmacology
|April 7, 2025
PubMed
Summary

Lenvatinib, a cancer drug, can cause Posterior Reversible Encephalopathy Syndrome (PRES), a condition with neurological symptoms and brain swelling. Early detection and stopping lenvatinib can help patients recover.

Keywords:
PRESadverse drug reactionshepatocellular carcinomalenvatinibposterior reversible encephalopathy syndrome

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

357

Related Experiment Videos

Last Updated: Jun 23, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

357

Area of Science:

  • Oncology
  • Neurology
  • Radiology

Background:

  • Posterior Reversible Encephalopathy Syndrome (PRES) presents with neurological deficits and reversible brain edema.
  • Lenvatinib is a multi-targeted kinase inhibitor used for hepatocellular carcinoma (HCC).
  • Lenvatinib-induced PRES is an emerging adverse effect requiring clinical attention.

Observation:

  • A 72-year-old female HCC patient on lenvatinib developed confusion, altered mental status, headaches, and severe hypertension.
  • Neuroimaging confirmed vasogenic edema in the brain's white matter, consistent with PRES.
  • Symptoms and brain abnormalities resolved after lenvatinib discontinuation.

Findings:

  • Lenvatinib therapy can precipitate PRES in HCC patients, even without prior hypertension.
  • Hypertension appears to be a key factor in the pathogenesis of lenvatinib-induced PRES.
  • Discontinuation of lenvatinib led to neurological and radiological improvement.

Implications:

  • This case highlights the importance of monitoring for PRES in HCC patients receiving lenvatinib.
  • Vigilant management of hypertension and prompt recognition of PRES symptoms are crucial for patient safety.
  • Understanding lenvatinib's potential neurotoxicity is vital for optimizing cancer treatment strategies.